C. Siwak-Tapp

ROS1 rearrangements define a unique molecular class of lung cancers.

Jeffrey W. Clark, Julie M. Batten, A. Iafrate, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.

D. Hsiang, V. Miller, Siraj M. Ali, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function

C. Cotman, C. Siwak-Tapp, N. Milgram, 2007, Neurobiology of Learning and Memory.

Region specific neuron loss in the aged canine hippocampus is reduced by enrichment

C. Cotman, C. Siwak-Tapp, N. Milgram, 2008, Neurobiology of Aging.

Heart rate decrease during crizotinib treatment and potential correlation to clinical response

S. Ou, C. Siwak-Tapp, Michele C. Azada, 2013, Cancer.

Neuroprotective effects of cognitive enrichment

Norton W. Milgram, Elizabeth Head, C. Siwak-Tapp, 2006, Ageing Research Reviews.